India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems
Aspen Biopharma Labs was hit with a warning letter from the FDA outlining multiple issues at an API facility in India, including poor building design that could lead to drug contamination.
